Valve risk leads to withdrawal of pergolide (Permax, Valiant)

Article

Two high-quality reports in the New England Journal of Medicine confirming the risk of valvulopathy with the use of pergolide (Permax, Valiant) have led the FDA to remove the drug from the U.S. market. Two generic forms of the drug, made by Teva and Par Pharmaceuticals, will also be withdrawn.

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
Related Content
Register Today: April 2024 Total Pharmacy Solutions Summit

Register Today: April 2024 Total Pharmacy Solutions Summit

April 1st 2024
Article

The can’t-miss event on April 13 features speakers and CE sessions focused on elevating patient-centric care.

Looking to the Future of Independent Pharmacy

Looking to the Future of Independent Pharmacy

July 13th 2022
Podcast

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

Flip The Pharmacy November Schedule & Sign-Ups

Flip The Pharmacy November Schedule & Sign-Ups

October 31st 2023
Article

Check out these can't-miss Workflow Wednesdays sessions.

Podcast: Pharmacy Financing With First Financial Bank

Podcast: Pharmacy Financing With First Financial Bank

January 28th 2022
Podcast

Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.

CPESN Names 2023 Outstanding Network Facilitator

CPESN Names 2023 Outstanding Network Facilitator

October 27th 2023
Article

The CPESN Outstanding Network Facilitator Award is sponsored by Compliant Pharmacy Alliance.

University of South Carolina Team Wins 2023 Good Neighbor Pharmacy NCPA Pruitt-Schutte Student Business Plan Competition

University of South Carolina Team Wins 2023 Good Neighbor Pharmacy NCPA Pruitt-Schutte Student Business Plan Competition

October 16th 2023
Article

The winner was announced during the 2023 NCPA Annual Convention and Expo.

© 2024 MJH Life Sciences

All rights reserved.